Introduction: Epilepsy affects more than 1% of the US population, and over 30% of adults
with epilepsy do not respond to antiseizure medications without life-impacting medication …

Controlled clinical trials in adults with medically intractable focal seizures treated with the
RNS® System demonstrate that closed-loop responsive neurostimulation to the seizure …

The RNS® System is the first commercially available device to provide closed-loop
responsive brain stimulation. The system includes a cranially implanted neurostimulator that …

The responsive neurostimulator (RNS®, NeuroPace Inc.) has been available clinically since
2013 for the treatment of medically refractory partial epilepsy. Using intracranial electrodes …

Closed-loop brain stimulation is one of the few treatments available for patients who are
ineligible for traditional surgical resection of the epileptogenic zone, due to having …

Abstract Objective The RNS System is a direct brain‐responsive neurostimulation system
that is US Food and Drug Administration–approved for adults with medically intractable focal …

The RNS System is an effective and safe adjunctive therapy in reducing the frequency of
seizures in a specific subset of patients. New applications, such as evaluation of epileptiform …

Epilepsy is a common chronic neurological disorder affecting∼ 1–2% of the population.
Despite the available treatment options (pharmacotherapy, surgery, and vagus nerve …

Objective Despite the overall success of responsive neurostimulation (RNS) therapy for drug‐
resistant focal epilepsy, clinical outcomes in individuals vary significantly and are hard to …

Objective Brain‐responsive neurostimulation (RNS System, NeuroPace) is used to treat
medically refractory focal epilepsy and also provides long‐term ambulatory …